About Cytarabine Liposomal
            
            Class: | Antineoplastic agent, Antimetabolite  
Use: | Treatment of lymphomatous meningitis due to non-Hodgkin lymphoma  
Adult dose: | 50 mg administered intrathecally (IT) once every 14 days; may be adjusted based on clinical response and tolerability  
Pediatric dose: | Safety and efficacy not established in pediatric patients; use is not recommended  
Side effects: | Nausea, vomiting, headache, fever, dizziness, and potential for neurotoxicity including seizures  
Contraindications: | Hypers
         
        
            
                
                
                    
                        Drug Class
                    
                    Antineoplastic agent, Antimetabolite
                 
                
                
                    
                        Uses & Indications
                    
                    Treatment of lymphomatous meningitis due to non-Hodgkin lymphoma
                 
                
                
                    
                        Storage Requirements
                    
                    Store at 20-25°C (68-77°F); protect from light; do not freeze
                 
                
                
                    
                        Manufacturer & Packaging
                    
                    
                        Manufacturer: Mundipharma GmbH, GERMANY
                    
                    
                    Package Size
                    1 Vial
                    
                    
                    Price & Supplier
                    
                        Price in UAE: AED 15972.40
                    
                    
                 
             
            
                
                
                    
                        Dosage Information
                    
                    
                        Adult Dose
                    
                    
                        50 mg administered intrathecally (IT) once every 14 days; may be adjusted based on clinical response and tolerability
                    
                    
                        Pediatric Dose
                    
                    
                        Safety and efficacy not established in pediatric patients; use is not recommended
                    
                 
                
                
                    
                        Side Effects
                    
                    Nausea, vomiting, headache, fever, dizziness, and potential for neurotoxicity including seizures
                 
             
         
        
        
            
                Contraindications & Precautions
            
            Hypersensitivity to cytarabine or any component of the formulation; concurrent use with other intrathecal therapies is not recommended
         
        
        
            
                Important Warnings
            
            Risk of serious neurological adverse reactions; monitor for signs of neurotoxicity; caution in patients with impaired renal function or those receiving other myelosuppressive agents
         
        
        
        
        
        
        
        
        
            
                Medical Disclaimer
            
            
                This information is for educational purposes only and should not replace professional medical advice. 
                Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication. 
                The information presented here is specific to medicines available in UAE pharmacies and is regularly updated 
                to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.